|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0007112,
umls-concept:C0027651,
umls-concept:C0194810,
umls-concept:C0205210,
umls-concept:C0205216,
umls-concept:C0205217,
umls-concept:C0475386,
umls-concept:C0549193,
umls-concept:C1306673,
umls-concept:C1511790,
umls-concept:C1521733,
umls-concept:C1705165,
umls-concept:C1710706,
umls-concept:C2700061
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2002-7-19
|
|
pubmed:abstractText |
Studies of radical prostatectomy specimens have suggested that the majority of prostate specific antigen detected (clinical stage T1c) tumors are clinically significant. We compared tumor location and pathological parameters in the radical prostatectomy specimens of stages T1c versus T2 cases in a 3-year period. The percent of stage T1c disease represented a stable majority of patients undergoing treatment for clinically localized prostate cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0022-5347
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
168
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
519-24
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:12131301-Adenocarcinoma,
pubmed-meshheading:12131301-Aged,
pubmed-meshheading:12131301-Humans,
pubmed-meshheading:12131301-Male,
pubmed-meshheading:12131301-Middle Aged,
pubmed-meshheading:12131301-Neoplasm Invasiveness,
pubmed-meshheading:12131301-Neoplasm Staging,
pubmed-meshheading:12131301-Prognosis,
pubmed-meshheading:12131301-Prostate,
pubmed-meshheading:12131301-Prostate-Specific Antigen,
pubmed-meshheading:12131301-Prostatectomy,
pubmed-meshheading:12131301-Prostatic Neoplasms,
pubmed-meshheading:12131301-Tumor Markers, Biological
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Pathological parameters of radical prostatectomy for clinical stages T1c versus T2 prostate adenocarcinoma: decreased pathological stage and increased detection of transition zone tumors.
|
|
pubmed:affiliation |
Department of Pathology, Vanderbilt Prostate Cancer Center and Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA.
|
|
pubmed:publicationType |
Journal Article
|
